Showing 2683 results
-
Press Release /In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis was shown to be…
-
Press Release /Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek…
-
Press Release /Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to…
-
Press Release /Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or…
-
Press Release /There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of…
-
Press Release /33 abstracts from the leading MS portfolio include data for Gilenya® (fingolimod), and investigational drugs siponimod (BAF312) and ofatumumab (OMB157) New research will be presented on…
-
Press Release /Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (…
-
Press Release /
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
Global resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®** Resolution paves way for 2018 launch in key European markets and… -
Key Release /Der Nettoumsatz steigt um 6% (kWk[1], +3% USD), vor allem dank folgender Beiträge: Cosentyx erzielt mit starken Volumenzuwächsen in allen Indikationen einen Umsatz von USD 750 Millionen (+37% kWk…
-
Press Release /Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] …